Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721483 | 0.85 | KDM4E (0.46) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL28704036 | 0.83 | KDM4E (0.53) | KDM4ERAB9ACYP3A4NPC1GAA | |
| Asparagine SCHEMBL6355509 | 0.83 | KDM4E (0.43) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL30904646 | 0.82 | MMP8 (0.48) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL8758916 | 0.81 | RAB9A (0.46) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL7270814 | 0.80 | KDM4E (0.41) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL8827773 | 0.79 | KDM4E (0.41) | KDM4ERAB9ACYP3A4NPC1CYP1A2 | |
| SCHEMBL31303189 | 0.77 | IDO1 (0.55) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL2622223 | 0.77 | IDO1 (0.55) | KDM4ERAB9ACYP3A4NPC1GAA | |
| SCHEMBL4406254 | 0.77 | RAB9A (0.52) | KDM4ERAB9ANPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | claimed |
| EP-4400164-A2 | A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES | Yeda Research and Development Co. Ltd (IL) | 2024-07-17 | — | — | EP | disclosed |
| EP-4400174-A2 | IMMUNOREGULATORY MOLECULES AND USES THEREFOR | The Francis Crick Institute Limited (GB) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240190919-A1 | PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME | IMMUNITY PHARMA LTD. (IL) | 2024-06-13 | — | — | US | disclosed |
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | ENTERA BIO LTD. (IL) | 2024-06-06 | — | — | US | disclosed |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11986522-B2 | Immunotherapeutic composition and uses thereof | ARA VAX PTY LTD (AU) | 2024-05-21 | — | — | US | disclosed |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11980658-B2 | Immunotherapeutic molecules and uses thereof | ARAVAX PTY LTD (AU) | 2024-05-14 | — | — | US | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
| EP-0745092-A1 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240181020-A1 | TREATMENT OF HYPOPARATHYROIDISM | PTH1R, PTMS, CYP24A1 | KDM4E 1710/4885RAB9A 3480/4885CYP3A4 4548/4885 |
| US-20240174730-A1 | VARIANT FC DOMAINS AND USES THEREOF | FCGR3B, FCGRT, FCGR2A | KDM4E 1597/4885RAB9A 888/4885CYP3A4 2762/4885 |
| US-20240156975-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | KDM4E 4753/4885RAB9A 1559/4885CYP3A4 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.